Non-Hodgkin Lymphoma News

Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk - The American Journal of Managed Care

Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk The American Journal of Managed Care

VB star Kenna Wollard diagnosed with non-Hodgkin lymphoma, on track to remission - Purdue Exponent

VB star Kenna Wollard diagnosed with non-Hodgkin lymphoma, on track to remission Purdue Exponent

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial - Nature

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial Nature

Former IVC, now Purdue volleyball star Kenna Wollard, shares cancer diagnosis, update - Yahoo Sports

Former IVC, now Purdue volleyball star Kenna Wollard, shares cancer diagnosis, update Yahoo Sports

Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs - Cureus

Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs Cureus

UNC Study Reveals Promising New Therapy for Non-Hodgkin Lymphoma - UNC Health

UNC Study Reveals Promising New Therapy for Non-Hodgkin Lymphoma UNC Health

Andrew M. Evens: Honored to Chair My Last In-Person Lymphoma Research Foundation SAB Meeting - Oncodaily

Andrew M. Evens: Honored to Chair My Last In-Person Lymphoma Research Foundation SAB Meeting Oncodaily

Purdue volleyball All-American reveals why she's out for season with positive prognosis - IndyStar

Purdue volleyball All-American reveals why she's out for season with positive prognosis IndyStar

Jeff Sharman, MD, on Advances in Non-Hodgkin Lymphoma Treatment - Targeted Oncology

Jeff Sharman, MD, on Advances in Non-Hodgkin Lymphoma Treatment Targeted Oncology

Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers

Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers

Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference - Health.com

Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference Health.com

National Poetry Month: "Non-Hodgkin’s Lymphoma" - The Rumpus

National Poetry Month: "Non-Hodgkin’s Lymphoma" The Rumpus

Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL - The ASCO Post

Mosunetuzumab With Response-Adapted Therapy in Previously Untreated NHL The ASCO Post

Advances in lymphoma treatment: new therapies and clinical trials - Penn Medicine

Advances in lymphoma treatment: new therapies and clinical trials Penn Medicine

7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore - Hartford HealthCare

7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore Hartford HealthCare

Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts - Nature

Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts Nature

Advanced and More Symptomatic B-Cell Non-Hodgkin Lymphoma at Diagnosis After COVID-19 Disruptions in a Romanian Tertiary Center - Cureus

Advanced and More Symptomatic B-Cell Non-Hodgkin Lymphoma at Diagnosis After COVID-19 Disruptions in a Romanian Tertiary Center Cureus

Lower Back Pain As the Initial Manifestation of Primary Follicular B-cell Non-Hodgkin Lymphoma of the Bone Marrow: A Case Report - Cureus

Lower Back Pain As the Initial Manifestation of Primary Follicular B-cell Non-Hodgkin Lymphoma of the Bone Marrow: A Case Report Cureus

Dural Follicular Non-Hodgkin Lymphoma Mimicking a Chronic Subdural Hematoma: A Case Report and Literature Review - Cureus

Dural Follicular Non-Hodgkin Lymphoma Mimicking a Chronic Subdural Hematoma: A Case Report and Literature Review Cureus

Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges - Cureus

Ureteral Involvement in Non-Hodgkin Lymphoma: A Rare Case Report With Diagnostic Challenges Cureus

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch

New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center

New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma - Nature

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma Nature

CD20-Positive B-Cell Non-Hodgkin Lymphoma Associated With Recurrent Acute Pancreatitis, Bilateral Renal Lesions, and Retroperitoneal Lymphadenopathy - Cureus

CD20-Positive B-Cell Non-Hodgkin Lymphoma Associated With Recurrent Acute Pancreatitis, Bilateral Renal Lesions, and Retroperitoneal Lymphadenopathy Cureus

Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics - Medical Xpress

Understanding the origins of Hodgkin lymphoma cells could lead to better diagnostics Medical Xpress

Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report - Frontiers

Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report Frontiers

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers

Real-World Liso-cel Data Show High Response Rates in R/R MCL - Oncology News Central

Real-World Liso-cel Data Show High Response Rates in R/R MCL Oncology News Central

Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin’s lymphoma - Nature

Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin’s lymphoma Nature

Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 - Precedence Research

Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 Precedence Research

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork

Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork

Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature - Frontiers

Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature Frontiers

Editorial: New molecular targets for personalized treatment for low-grade non-hodgkin lymphoma - Frontiers

Editorial: New molecular targets for personalized treatment for low-grade non-hodgkin lymphoma Frontiers

Delayed Autoimmune Hemolytic Anemia After Remission in Non-Hodgkin Lymphoma - Cureus

Delayed Autoimmune Hemolytic Anemia After Remission in Non-Hodgkin Lymphoma Cureus

Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report - Frontiers

Metachronous multiple primary cancers involving pulmonary non-Hodgkin lymphoma and bladder cancer: a case report Frontiers

CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight - Yahoo Finance

CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight Yahoo Finance